Tamsulosin Assisted Ureteral Access Sheath Insertion

Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy: the Impact of One Week of Pre-operative Tamsulosin

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05197088

Enrollment

110

Registered

2022-01-19

Start date

2022-01-09

Completion date

2023-07-31

Last updated

2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Stone, Retrograde Intrarenal Surgery, Urolithiasis

Brief summary

Aim is to study if 1 week of pre operative tamsulosin would enable easier insertion of ureteral access sheath in primary retrograde intrarenal surgery for renal stone disease

Interventions

DRUGTamsulosin

1 week of tamsulosin

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* renal stone undergoing retrograde intrarenal surgery

Exclusion criteria

* not on tamsulosin or other alpha blockers regularly * ureteral stricture * concurrent ureteric stone

Design outcomes

Primary

Measure	Time frame
successful insertion of ureteral access sheath to the upper ureter (above the level of SI joint on fluoroscopy)	during operation

Secondary

Measure	Time frame
grade of ureteric injury after ureteral access sheath removal	during operation
post operative complications	3 months
stone free rate	3 months
need for additional procedures	3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026